Search

XL844

XL844 is investigated for the use and treatment solid tumors. XL844 is a solid. … XL844 is a potent inhibitor of the checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to a variety of DNA damaging agents.

AZD-8330

AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.

Satraplatin

As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies. … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

LJP 1082

LJP 1082 is a Toleragen that is designed to shut down the B cells that produce antibodies to ß2 GP1. … The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.

Vernakalant

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. … Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA.

Melengestrol

Melengestrol is a steroidal progestin and antineoplastic agent which was never marketed. An acylated derivative, melengestrol acetate, is used as a growth promoter in animals.

Glutamic acid

A peptide that is a homopolymer of glutamic acid.

Histapyrrodine

Oregovomab

Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.

Emepronium